Cite as: J. Zhu *et al.*, *Science*
10.1126/science.abd5491 (2021).

Mitochondrial NADP(H) generation is essential for proline biosynthesis

Jiajun Zhu¹, Simon Schwörer^{1†}, Mirela Berisa^{2†}, Yeon Ju Kyung^{1†}, Keun Woo Ryu¹, Junmei Yi³, Xuejun Jiang³, Justin R. Cross², Craig B. Thompson^{1*}

¹Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. ²The Donald B. and Catherine C. Marron Cancer Metabolism Center, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. ³Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

†These authors contributed equally to this work.

*Corresponding author. Email: thompsonc@mskcc.org

The coenzyme nicotinamide adenine dinucleotide phosphate (NADP⁺) and its reduced form (NADPH) regulate reductive metabolism in a subcellularly compartmentalized manner. Mitochondrial NADP(H) production depends on the phosphorylation of NAD(H) by NAD kinase 2 (NADK2). Deletion of *NADK2* in human cell lines did not alter mitochondrial folate pathway activity, tricarboxylic acid cycle activity, or mitochondrial oxidative stress, but led to impaired cell proliferation in minimal medium. This growth defect was rescued by proline supplementation. NADK2-mediated mitochondrial NADP(H) generation was required for the reduction of glutamate and hence proline biosynthesis. Furthermore, mitochondrial NADP(H) availability determined the production of collagen proteins by cells of mesenchymal lineage. Thus, a primary function of the mitochondrial NADP(H) pool is to support proline biosynthesis for use in cytosolic protein synthesis.

Mammalian cells depend on the inter-conversion of nicotinamide adenine dinucleotide phosphate molecules between the oxidized (NADP⁺) and reduced (NADPH) forms to support reductive biosynthesis and to maintain cellular antioxidant defense. NADP⁺ and NADPH molecules [NADP(H) hereafter] are unable to cross subcellular membranes (1, 2). As a result, cellular pools of NADP(H) are compartmentalized. In the cytosol, NADP(H) is derived from nicotinamide adenine dinucleotide [NAD(H)] by NAD kinase (NADK, referred to as NADK1 hereafter). Cytosolic NADPH acts as a substrate in fatty acid biosynthesis, and as the reducing equivalent required to regenerate reduced glutathione (GSH) and thioredoxin for antioxidant defense. Mitochondria host a number of biosynthetic activities critical for cellular metabolism but are also major sites for reactive oxygen species (ROS) generation. Mammalian mitochondrial NAD kinase (NADK2) converts NAD(H) to NADP(H) through phosphorylation (3).

Using subcellular fractionation, we confirmed that NADK2 purified in the membrane-associated fraction in cultured human cell lines (fig. S1, A to C). Mitochondria immunopurification (Mito-IP, (4, 5)) from DLD1 cells following CRISPR-Cas9 deletion of *NADK2* (fig. S1D) resulted in a metabolomic profile consistent with mitochondrial metabolism, and metabolites known to be excluded from the mitochondrial compartment were minimally detected (Fig. 1A; fig. S1, E to G; and table S1). We examined NADP(H) levels in

immunopurified mitochondria using an adapted enzyme cycling assay (6). Although total NADP(H) abundance or NADP⁺ to NADPH ratio were not changed at whole cell level upon NADK2 loss as previously reported (6, 7), mitochondrial NADP(H) abundance was reduced by more than 80% ($P < 0.001$) in *NADK2* knockout cells (Fig. 1, B and C, and fig. S1, H to J). NAD(H) abundance or NAD⁺ to NADH ratio were not altered by *NADK2* knockout in whole cells or in mitochondria (fig. S1, K to N).

Oncogenic mutant forms of isocitrate dehydrogenase 1 (IDH1) and IDH2 require cytosolic and mitochondrial NADPH, respectively, to produce 2-hydroxyglutarate (2HG) from α -ketoglutarate (α KG) (8) (fig. S1O). We deleted the *NADK2* gene in chondrosarcoma cell lines that had either an endogenous IDH1 R132 mutation (JJ012) or IDH2 R172 mutation (CS1) (Fig. 1D). Loss of NADK2 resulted in reduced 2HG abundance ($P < 0.001$) in CS1 cells, but not in JJ012 cells (Fig. 1, E and F). We further subjected control and *NADK2*-deleted CS1 cells to a xenograft tumor assay in vivo and observed similarly decreased 2HG abundance in tumors formed by *NADK2* knockout cells (Fig. 1G). These results confirmed that NADK2 is required to maintain the mitochondrial NADP(H) pool.

Methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) and MTHFD2-like (MTHFD2L) use either NAD⁺ or NADP⁺ as electron acceptors in the mitochondrial folate pathway.

Using [2,3,3-²H₃]serine isotope tracing, cells lacking *MTHFD2* or serine hydroxymethyltransferase 2 (*SHMT2*) both displayed an increase in doubly labeled thymidine triphosphate (TTP M+2) when compared to control cells (Fig. 2, A to C, and fig. S2, A and B), suggesting decreased mitochondrial folate pathway activity and increased cytosolic serine catabolism, as previously reported (9, 10). By contrast, cells lacking *NADK2* maintained the fraction of singly labeled (TTP M+1) derived from [2,3,3-²H₃]serine (Fig. 2, A to C, and fig. S2, A and B), indicating the mitochondrial folate pathway is not disrupted by *NADK2* loss.

We performed isotope tracing experiments with uniformly labeled [U-¹³C]glucose or [U-¹³C]glutamine comparing control and *NADK2*-deleted cells to analyze tricarboxylic acid (TCA) cycle activity. We did not observe consistent changes in the TCA cycle intermediates derived from either glucose or glutamine (Fig. 2, D to G, and fig. S2, C to V). In addition, *NADK2*-deletion did not lead to changes in the mitochondrial basal oxygen consumption rate or uncoupled electron transport chain activity (fig. S2, W to Y).

Mitochondria are major sites of ROS generation in cells (11), and depletion of mitochondrial NADP(H) is thought to lead to oxidative stress. However, in all cell types that we tested, cells lacking *NADK2* did not display increased cellular ROS or mitochondrial superoxide (MitoSox) abundance (Fig. 2H and fig. S3, A to G). We used mitochondria-targeted redox-sensitive green fluorescence protein (roGFP2) constructs coupled to the yeast peroxidase Orp1 or human glutaredoxin-1 (Grx1) (12, 13), and measured similar amounts of mitochondrial H₂O₂ or GSH oxidation, respectively, in control and *NADK2* knockout cells (Fig. 2I and fig. S3, H to J). Treatment with MitoParaquat (MitoPQ) increased the expression of enzymes involved in GSH synthesis to a similar extent in cells lacking *NADK2* as that in the control cells (14) (fig. S3, K and L). In agreement, loss of *NADK2* did not alter cellular or mitochondrial GSH abundance or the ratio of GSH to its oxidized form GSSG (GSH/GSSG) (fig. S3, M to P). [U-¹³C]glutamine tracing revealed no significant changes in the fraction of GSH or GSSG derived from glutamine upon *NADK2* loss (fig. S3, Q and R). These results are consistent with the cytosolic NADP(H) pool, but not mitochondrial NADP(H), being critical for maintaining cellular GSH levels to prevent oxidative damage (7). Glutathione reductase (GSR) expression was absent in the mitochondrial fraction (Fig. 2J), thus the NADPH-dependent GSH reduction appears not to take place in mitochondria.

Hyper-oxidation of peroxiredoxins (PRXs-SO₃) indicates oxidative stress of the cellular thioredoxin system. We observed similar amounts of mitochondrial (PRX3), as well as cytosolic and nuclear (PRX1 and PRX2) peroxiredoxin oxidation, when comparing cells lacking *NADK2* with control cells (Fig. 2K and fig. S3, S and T). Cellular and mitochondrial

oxidative stress can lead to ferroptotic cell death (15, 16). When treated with Erastin or RSL3, chemicals that induce ferroptosis, cells lacking *NADK2* showed no increase in cell death (Fig. 2L and fig. S3U). Similarly, *Nadk2* knockout did not increase sensitivity to ferroptosis in contact-inhibited, non-proliferative mouse embryonic fibroblasts (MEFs) (fig. S3, V and W). Thus, loss of *NADK2*, and depletion of mitochondrial NADP(H), did not increase oxidative stress under the experimental conditions we examined, although it remains possible that mitochondrial NADP(H) generation might play a role in antioxidant defense in response to other physiological perturbations.

We observed that proliferation of cells lacking *NADK2* was not perturbed compared to that of control cells when cultured in a nutrient rich medium (DMEM/F12) (fig. S4, A to D). However, our studies of IDH2-mutant cells indicated that *NADK2* could have a role in NADPH-dependent biosynthesis (Fig. 1, F and G). To test whether mitochondrial NADP(H) supports biosynthetic reactions in general, we subjected control and *NADK2* knockout cells to culture medium composed of minimal essential nutrients (DMEM) and found that the growth of *NADK2*-deleted cells was compromised (fig. S4, A to D). Apparently, mitochondrial NADP(H) promotes the synthesis of one or more nutrients required to sustain cell proliferation.

Growth of cells lacking *NADK2* was restored in DMEM by supplementing non-essential amino acids (NEAAs), but not by other nutrients present in DMEM/F12 (Fig. 3A and fig. S4, E and F). Supplementing individual amino acids revealed that proline was both necessary and sufficient to restore proliferation of *NADK2* knockout cells in DMEM (Fig. 3B and fig. S4, G to J). In agreement, cells lacking *NADK2* showed reduced intracellular proline abundance (Fig. 3C). Similar results were obtained under hypoxia (0.5% O₂) (fig. S4, K to M). To validate that the proline-dependent growth phenotype was the result of *NADK2* loss, we introduced *NADK2* cDNA resistant to CRISPR-Cas9 mediated genome editing into the *NADK2* knockout cells, which restored both intracellular proline abundance and cell growth (Fig. 3, D to F, and fig. S5, A to C). Similar results were observed when the yeast mitochondrial NAD(H) kinase, POS5 (17), was reconstituted in *NADK2*-deficient cells (Fig. 3, G to I, and fig. S5, D to F).

We performed metabolite profiling of cells lacking *NADK2* cultured in DMEM, and confirmed the depletion of intracellular proline, while amounts of many other amino acids were slightly increased (Fig. 4A and fig. S6, A and B). Loss of *NADK2* also reduced proline abundance in non-proliferating (contact-inhibited) MEFs (fig. S6, C and D). By contrast, loss of cytosolic *NADK1* did not decrease proline abundance (fig. S6, E and F). Likewise, the oxygen-dependent NADPH oxidase, TPNOX (18), reduced proline amounts when expressed in mitochondria (mitoTPNOX) but not in cytosol

(cytoTPNOX) (fig. S6, G to J). To extend these observations, we examined the consumption of nutrients from the proline-containing DMEM/F12 medium. While we observed net proline accumulation in medium conditioned by control cells, proline was consumed by cells lacking *NADK2* (Fig. 4, B and C, and fig. S7, A to D). In addition, glutamate accumulation was found in medium conditioned by cells lacking *NADK2* (Fig. 4, B and D, and fig. S7, A, B, E, and F), which might result from compensatory accumulation of carbon and nitrogen in the form of glutamate instead of proline. We performed similar analyses in xenograft tumors formed by CS1 cells (Fig. 1). We found that across a panel of amino acids, proline amount was reduced in tumors formed by CS1 cells lacking *NADK2* (Fig. 4E and fig. S7G), which correlated with a slower growth rate of these tumors compared to those formed by control cells (fig. S7H). Mice grafted with control or *NADK2* knockout cells displayed similar plasma levels of proline as well as other amino acids at the time of tumor resection (fig. S7I). Thus, loss of *NADK2*, and the consequent depletion of mitochondrial NADP(H), results in proline auxotrophy.

Proline biosynthesis takes place in the mitochondria, where glutamine-derived glutamate is converted to pyrroline-5-carboxylate (P5C) by pyrroline-5-carboxylate synthase (P5CS). P5C is further reduced to proline by mitochondrial pyrroline-5-carboxylate reductases (PYCR1 and PYCR2) (Fig. 4F). [^{13}C]glutamine tracing revealed that most cellular glutamate and proline were derived from glutamine, and that glutamine-derived proline was reduced upon *NADK2* loss (Fig. 4, G and H, and fig. S8, A and B). By contrast, proline abundance was not perturbed when the cytosolic pyrroline-5-carboxylate reductase (PYCR1) was deleted (fig. S8, C and D).

P5CS is an NADPH-dependent enzyme, whereas PYCR1 and PYCR2 have higher affinity for NADH than for NADPH (19–21). To test if loss of *NADK2* impairs conversion of glutamate to P5C by P5CS, we took advantage of the fact that cellular P5C is in equilibrium with glutamate-5-semialdehyde (GSA), which can be diverted to produce ornithine for polyamine biosynthesis (Fig. 4F). Intracellular arginine can also contribute to ornithine and polyamines. Isotope tracing using [^{13}C]glutamine and [^{13}C]arginine allowed us to assess the relative contribution of these pathways to polyamine production (fig. S8E). The fraction of ornithine and putrescine derived from [^{13}C]glutamine decreased in cells lacking *NADK2*, indicating that P5CS flux from glutamate to P5C and GSA was diminished (Fig. 4, I and J). This also resulted in a reciprocal increase in the proportional contribution of arginine to ornithine and putrescine (fig. S8, F to I). Because ornithine transcarbamylase expression is restricted to the liver and small intestine, loss of *NADK2* did not change glutamine or arginine contribution to cellular citrulline (fig. S8, J and K). Thus, loss of *NADK2* and the resulting decrease in

mitochondrial NADP(H) blocks the reduction of glutamate to P5C required for proline biosynthesis.

Incorporation of the proline pyrrolidine ring slows protein translation (22, 23), but endows proline-containing polypeptides with conformational rigidity. As a result, proline and its post-translationally modified form, hydroxyproline, are abundant in collagen proteins (24), so a consequence of decreased mitochondrial NADP(H) generation could be impaired collagen production. Cultured mouse fibroblasts lacking *Nadk2* had decreased expression of collagen when grown in DMEM (Fig. 4K and fig. S9A). These cells accumulated activating transcription factor 4 (ATF4), indicative of amino acid shortage. Addition of 300 μM proline to the culture medium restored collagen expression and blunted ATF4 accumulation in cells lacking *Nadk2* (Fig. 4K and fig. S9, A and B). Similar results were obtained in osteosarcoma and chondrosarcoma cells that produce collagens (fig. S9, C and D). Fibroblasts lacking *Nadk2* showed decreased collagen secretion, which was rescued by proline supplementation to the medium (Fig. 4, L and M). In patients with idiopathic pulmonary fibrosis (IPF) (25), higher *NADK2* expression in the lung correlated with lower forced vital capacity (FVC) ($P = 0.007$) and diffusion capacity for carbon monoxide (DLCO) ($P = 0.015$), parameters that measure maximum air exhalation and the ability of lung to transfer air into the blood, respectively (Fig. 4, N and O). Similarly, IPF patients with both high *NADK2* and high *P5CS* expression in the lung had reduced FVC and DLCO values compared to those with low *NADK2* and low *P5CS* expression (fig. S9, E and F). Thus, increased expression of *NADK2* correlated with enhanced fibrotic diseases characterized by excessive collagen deposition.

These findings provide insights into the regulation of intracellular metabolism. In endosymbiosis with the host cell, mitochondria produce NADP(H) that supplies biosynthetic precursors to their host and appear not to use the NADP(H) for antioxidant defense in support of their own homeostasis. Compartmentalization of cellular metabolism thus has important roles in eukaryotic cells beyond the well-known collaborative production of ATP.

REFERENCES AND NOTES

1. R. P. Goodman, S. E. Calvo, V. K. Mootha, Spatiotemporal compartmentalization of hepatic NADH and NADPH metabolism. *J. Biol. Chem.* **293**, 7508–7516 (2018). [doi:10.1074/jbc.TM117.000258](https://doi.org/10.1074/jbc.TM117.000258) [Medline](#)
2. C. A. Lewis, S. J. Parker, B. P. Fiske, D. McCloskey, D. Y. Gui, C. R. Green, N. I. Vokes, A. M. Feist, M. G. Vander Heiden, C. M. Metallo, Tracing compartmentalized NADPH metabolism in the cytosol and mitochondria of mammalian cells. *Mol. Cell* **55**, 253–263 (2014). [doi:10.1016/j.molcel.2014.05.008](https://doi.org/10.1016/j.molcel.2014.05.008) [Medline](#)
3. K. Ohashi, S. Kawai, K. Murata, Identification and characterization of a human mitochondrial NAD kinase. *Nat. Commun.* **3**, 1248 (2012). [doi:10.1038/ncomms2262](https://doi.org/10.1038/ncomms2262) [Medline](#)
4. W. W. Chen, E. Freinkman, D. M. Sabatini, Rapid immunopurification of mitochondria for metabolite profiling and absolute quantification of matrix metabolites. *Nat. Protoc.* **12**, 2215–2231 (2017). [doi:10.1038/nprot.2017.104](https://doi.org/10.1038/nprot.2017.104) [Medline](#)

5. W. W. Chen, E. Freinkman, T. Wang, K. Birsoy, D. M. Sabatini, Absolute Quantification of Matrix Metabolites Reveals the Dynamics of Mitochondrial Metabolism. *Cell* **166**, 1324–1337.e11 (2016). [doi:10.1016/j.cell.2016.07.040](https://doi.org/10.1016/j.cell.2016.07.040) [Medline](#)
6. G. Hoxhaj, I. Ben-Sahra, S. E. Lockwood, R. C. Timson, V. Byles, G. T. Henning, P. Gao, L. M. Selfors, J. M. Asara, B. D. Manning, Direct stimulation of NADP⁺ synthesis through Akt-mediated phosphorylation of NAD kinase. *Science* **363**, 1088–1092 (2019). [doi:10.1126/science.aau3903](https://doi.org/10.1126/science.aau3903) [Medline](#)
7. C. C. Ding, J. Rose, T. Sun, J. Wu, P.-H. Chen, C.-C. Lin, W.-H. Yang, K.-Y. Chen, H. Lee, E. Xu, S. Tian, J. Akinwuntan, J. Zhao, Z. Guan, P. Zhou, J.-T. Chi, MESH1 is a cytosolic NADPH phosphatase that regulates ferroptosis. *Nat. Metab.* **2**, 270–277 (2020). [doi:10.1038/s42255-020-0181-1](https://doi.org/10.1038/s42255-020-0181-1) [Medline](#)
8. A. H. Shih, O. Abdel-Wahab, J. P. Patel, R. L. Levine, The role of mutations in epigenetic regulators in myeloid malignancies. *Nat. Rev. Cancer* **12**, 599–612 (2012). [doi:10.1038/nrc3343](https://doi.org/10.1038/nrc3343) [Medline](#)
9. G. S. Ducker, L. Chen, R. J. Morscher, J. M. Ghergurovich, M. Esposito, X. Teng, Y. Kang, J. D. Rabinowitz, Reversal of Cytosolic One-Carbon Flux Compensates for Loss of the Mitochondrial Folate Pathway. *Cell Metab.* **23**, 1140–1153 (2016). [doi:10.1016/j.cmet.2016.04.016](https://doi.org/10.1016/j.cmet.2016.04.016) [Medline](#)
10. N. Kory, G. A. Wyant, G. Prakash, J. uit de Bos, F. Bottanelli, M. E. Pacold, S. H. Chan, C. A. Lewis, T. Wang, H. R. Keys, Y. E. Guo, D. M. Sabatini, SFXN1 is a mitochondrial serine transporter required for one-carbon metabolism. *Science* **362**, eaat9528 (2018). [doi:10.1126/science.aat9528](https://doi.org/10.1126/science.aat9528) [Medline](#)
11. H. Kong, N. S. Chandel, Regulation of redox balance in cancer and T cells. *J. Biol. Chem.* **293**, 7499–7507 (2018). [doi:10.1074/jbc.TM117.000257](https://doi.org/10.1074/jbc.TM117.000257) [Medline](#)
12. M. Gutscher, A.-L. Pauleau, L. Marty, T. Brach, G. H. Wabnitz, Y. Samstag, A. J. Meyer, T. P. Dick, Real-time imaging of the intracellular glutathione redox potential. *Nat. Methods* **5**, 553–559 (2008). [doi:10.1038/nmeth.1212](https://doi.org/10.1038/nmeth.1212) [Medline](#)
13. M. Gutscher, M. C. Sobotta, G. H. Wabnitz, S. Ballikaya, A. J. Meyer, Y. Samstag, T. P. Dick, Proximity-based protein thiol oxidation by H₂O₂-scavenging peroxidases. *J. Biol. Chem.* **284**, 31532–31540 (2009). [doi:10.1074/jbc.M109.059246](https://doi.org/10.1074/jbc.M109.059246) [Medline](#)
14. E. L. Robb, J. M. Gawel, D. Aksentijevic, H. M. Cochemé, T. S. Stewart, M. M. Shchepinova, H. Qiang, T. A. Prime, T. P. Bright, A. M. James, M. J. Shattock, H. M. Senn, R. C. Hartley, M. P. Murphy, Selective superoxide generation within mitochondria by the targeted redox cyclers MitoParaquat. *Free Radic. Biol. Med.* **89**, 883–894 (2015). [doi:10.1016/j.freeradbiomed.2015.08.021](https://doi.org/10.1016/j.freeradbiomed.2015.08.021) [Medline](#)
15. M. Gao, J. Yi, J. Zhu, A. M. Minikes, P. Monian, C. B. Thompson, X. Jiang, Role of Mitochondria in Ferroptosis. *Mol. Cell* **73**, 354–363.e3 (2019). [doi:10.1016/j.molcel.2018.10.042](https://doi.org/10.1016/j.molcel.2018.10.042) [Medline](#)
16. B. R. Stockwell, J. P. Friedmann Angeli, H. Bayir, A. I. Bush, M. Conrad, S. J. Dixon, S. Fulda, S. Gascón, S. K. Hatzios, V. E. Kagan, K. Noel, X. Jiang, A. Linkermann, M. E. Murphy, M. Overholtzer, A. Oyagi, G. C. Pagnussat, J. Park, Q. Ran, C. S. Rosenfeld, K. Salnikow, D. Tang, F. M. Torti, S. V. Torti, S. Toyokuni, K. A. Woerpel, D. D. Zhang, Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. *Cell* **171**, 273–285 (2017). [doi:10.1016/j.cell.2017.09.021](https://doi.org/10.1016/j.cell.2017.09.021) [Medline](#)
17. C. E. Outten, V. C. Culotta, A novel NADH kinase is the mitochondrial source of NADPH in *Saccharomyces cerevisiae*. *EMBO J.* **22**, 2015–2024 (2003). [doi:10.1093/emboj/cdg211](https://doi.org/10.1093/emboj/cdg211) [Medline](#)
18. V. Cracan, D. V. Titov, H. Shen, Z. Grabarek, V. K. Mootha, A genetically encoded tool for manipulation of NADP⁺/NADPH in living cells. *Nat. Chem. Biol.* **13**, 1088–1095 (2017). [doi:10.1038/nchembio.2454](https://doi.org/10.1038/nchembio.2454) [Medline](#)
19. J. De Ingeniis, B. Ratnikov, A. D. Richardson, D. A. Scott, P. Aza-Blanc, S. K. De, M. Kazanov, M. Pellecchia, Z. Ronai, A. L. Osterman, J. W. Smith, Functional specialization in proline biosynthesis of melanoma. *PLOS ONE* **7**, e45190 (2012). [doi:10.1371/journal.pone.0045190](https://doi.org/10.1371/journal.pone.0045190) [Medline](#)
20. J. J. Kramer, R. C. Gooding, M. E. Jones, A radiochemical assay for a NADP⁺-specific γ -glutamate semialdehyde dehydrogenase extracted from mitochondrial membrane of rat intestinal epithelial cells. *Anal. Biochem.* **168**, 380–386 (1988). [doi:10.1016/0003-2697\(88\)90333-8](https://doi.org/10.1016/0003-2697(88)90333-8) [Medline](#)
21. J. M. Phang, Proline Metabolism in Cell Regulation and Cancer Biology: Recent Advances and Hypotheses. *Antioxid. Redox Signal.* **30**, 635–649 (2019). [doi:10.1089/ars.2017.7350](https://doi.org/10.1089/ars.2017.7350) [Medline](#)
22. M. Y. Pavlov, R. E. Watts, Z. Tan, V. W. Cornish, M. Ehrenberg, A. C. Forster, Slow peptide bond formation by proline and other *N*-alkylamino acids in translation. *Proc. Natl. Acad. Sci. U.S.A.* **106**, 50–54 (2009). [doi:10.1073/pnas.0809211106](https://doi.org/10.1073/pnas.0809211106) [Medline](#)
23. F. Loayza-Puch, K. Rooijers, L. C. M. Buil, J. Zijlstra, J. F. Oude Vrielink, R. Lopes, A. P. Ugalde, P. van Breugel, I. Hofland, J. Wesseling, O. van Tellingen, A. Bex, R. Agami, Tumour-specific proline vulnerability uncovered by differential ribosome codon reading. *Nature* **530**, 490–494 (2016). [doi:10.1038/nature16982](https://doi.org/10.1038/nature16982) [Medline](#)
24. S. Schwörer, M. Berisa, S. Violante, W. Qin, J. Zhu, R. C. Hendrickson, J. R. Cross, C. B. Thompson, Proline biosynthesis is a vent for TGF β -induced mitochondrial redox stress. *EMBO J.* **39**, e103334 (2020). [doi:10.15252/emboj.2019103334](https://doi.org/10.15252/emboj.2019103334) [Medline](#)
25. I. V. Yang, C. D. Coldren, S. M. Leach, M. A. Seibold, E. Murphy, J. Lin, R. Rosen, A. J. Neidermyer, D. F. McKean, S. D. Groshong, C. Cool, G. P. Cosgrove, D. A. Lynch, K. K. Brown, M. I. Schwarz, T. E. Fingerlin, D. A. Schwartz, Expression of cilium-associated genes defines novel molecular subtypes of idiopathic pulmonary fibrosis. *Thorax* **68**, 1114–1121 (2013). [doi:10.1136/thoraxjnl-2012-202943](https://doi.org/10.1136/thoraxjnl-2012-202943) [Medline](#)
26. P. S. Ward, C. Lu, J. R. Cross, O. Abdel-Wahab, R. L. Levine, G. K. Schwartz, C. B. Thompson, The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization. *J. Biol. Chem.* **288**, 3804–3815 (2013). [doi:10.1074/jbc.M112.435495](https://doi.org/10.1074/jbc.M112.435495) [Medline](#)
27. L. Salamanca-Cardona, H. Shah, A. J. Poot, F. M. Correa, V. Di Galleonardo, H. Lui, V. Z. Miloushev, K. L. Granlund, S. S. Tee, J. R. Cross, C. B. Thompson, K. R. Keshari, *In Vivo* Imaging of Glutamine Metabolism to the Oncometabolite 2-Hydroxyglutarate in IDH1/2 Mutant Tumors. *Cell Metab.* **26**, 830–841.e3 (2017). [doi:10.1016/j.cmet.2017.10.001](https://doi.org/10.1016/j.cmet.2017.10.001) [Medline](#)
28. S. Baghirova, B. G. Hughes, M. J. Hendzel, R. Schulz, Sequential fractionation and isolation of subcellular proteins from tissue or cultured cells. *MethodsX* **2**, 440–445 (2015). [doi:10.1016/j.mex.2015.11.001](https://doi.org/10.1016/j.mex.2015.11.001) [Medline](#)

ACKNOWLEDGMENTS

We thank members of the Thompson laboratory for critical discussions during manuscript preparation. We thank Elisa de Stanchina for assistance with tumor xenograft experiments, and Sara Violante for assistance with LC-MS experiments. **Funding:** J.Z. is supported by the Leukemia and Lymphoma Society (5460-18) and the NCI (1K99CA248711). S.S. is supported by the Human Frontier Science Program (LT000854/2018-L), the European Molecular Biology Organization (ALTF 467-2018), and the Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center. K.W.R. is supported by the Hunter Douglas Fellowship in Breast Cancer Research (13459) and the BRIA Postdoctoral Researcher Innovation Grant (18057). J.R.C. is supported by grants from the NIAID (R25 training grant AI140472-01A1) and the Donald B. and Catherine C. Marron Cancer Metabolism Center. X.J. is supported by grants from the NIH (R01CA204232 and R01CA166413). This work is supported by grants from the NCI (C.B.T.) and by the cancer center support grant (P30 CA008748) to Memorial Sloan Kettering Cancer Center. **Author contributions:** J.Z. and C.B.T. conceived the study. J.Z. performed most experiments and analyzed the data, with assistance from Y.J.K. S.S. performed some of the experiments in mouse fibroblasts, analyzed IPF datasets and optimized experimental methods used in this study. M.B. performed LC-MS measurements and analyses under the supervision of J.R.C. K.W.R. contributed key reagents and experimental methods. J.Y. and X.J. performed ferroptosis assays. J.Z. and C.B.T. interpreted the results and wrote the manuscript. All authors participated in discussing and finalizing the manuscript. **Competing interests:** C.B.T. is a founder of Agios Pharmaceuticals and a member of its scientific advisory board. He is also a former member of the Board of Directors and stockholder of Merck and Charles River Laboratories. He holds patents related to cellular metabolism. X.J. holds patents related to autophagy and cell death. **Data and materials availability:** All data are available in the manuscript or supplementary materials.

SUPPLEMENTARY MATERIALS

science.sciencemag.org/cgi/content/full/science.abd5491/DC1
Materials and Methods
Figs. S1 to S9

Tables S1 and S2
References (26–28)
MDAR Reproducibility Checklist

27 June 2020; accepted 7 April 2021
Published online 22 April 2021
10.1126/science.abd5491

NADK2 is required to maintain the mitochondrial NADP(H) pool

Fig. 1. NADK2 is required to maintain the mitochondrial NADP(H) pool. (A) DLD1 cells expressing HA-tagged OMP25 protein (DLD1-OMP25HA) were engineered to express control guide RNA (sgCtrl) or two independent guide RNA sequences targeting *NADK2* (sgNADK2-1 and sgNADK2-2), and were subjected to Western blot of whole cell or anti-HA immunopurified mitochondria (Mito-IP). (B and C) Colorimetric enzyme-based measurement of total NADP(H) abundance in (B) whole cell or (C) immunopurified mitochondria of DLD1-OMP25HA cells with sgCtrl, sgNADK2-1, or sgNADK2-2, cultured in DMEM/F12 medium. (D) Western blot analysis of JJ012 (mutant IDH1) and CS1 (mutant IDH2) cells with sgCtrl, sgNADK2-1, or sgNADK2-2. (E and F) 2HG abundance measured by gas chromatography-mass spectrometry (GC-MS) in (E) JJ012 and (F) CS1 cells with sgCtrl, sgNADK2-1, or sgNADK2-2. (G) 2HG abundance measured by GC-MS in xenograft tumors formed by CS1 cells with sgCtrl or sgNADK2-2. Error bars in (B) represent mean + SD, n = 6; in (C), (E) and (F) represent mean + SD, n = 3; in (G) represent mean ± SD, n = 10. In (C), one-way ANOVA was performed with matched measures. In (F), one-way ANOVA was performed. In (G), two-sided *t*-test was performed with Welch's correction. ****P* < 0.001.

Mitochondrial NADP(H) depletion has minimal effect on folate pathway and TCA cycle activity

Fig. 2. Mitochondrial NADP(H) depletion does not have significant effects on folate pathway, TCA cycle activity, or measures of oxidative stress. (A) Scheme of the tracing strategy, adapted from (9, 10). Catabolism of [2,3,3-²H₃]serine in the mitochondrial or cytosolic folate pathway produces singly or doubly deuterated thymidine triphosphate (TTP M+1 or TTP M+2), respectively. (B) Western blot of DLD1 cells with sgCtrl, sgNADK2-1, sgNADK2-2, sgMTHFD2, or sgSHMT2. (C) Isotopologue distribution of TTP measured by liquid chromatography-mass spectrometry (LC-MS) in DLD1 cells denoted in (B), cultured in [2,3,3-²H₃]serine-containing medium for 8 hours. (D to G) Isotopologue distribution of the indicated metabolites measured by GC-MS in DLD1 cells with sgCtrl, sgNADK2-1, or sgNADK2-2, cultured in [U-¹³C]glutamine-containing medium for 6 hours. (H) Cellular ROS measured by CM-H₂DCFDA in the indicated DLD1 cells, mock treated or treated with 150 μM H₂O₂ for 4 hours. (I) DLD1 cells expressing Mito-Orp1-roGFP2 and the indicated guide RNA were treated with vehicle (DMSO) or 100 μM MitoPQ for 24 hours. Oxidation status was expressed as percentage of maximal oxidation which was determined by treating cells with 5 mM H₂O₂ for 5 min before harvest. (J) Western blot analysis of whole cell or immunopurified mitochondria of DLD1-OMP25HA cells expressing the indicated guide RNA (K) Western blot of the indicated DLD1 cells mock treated or treated with 500 μM H₂O₂ for 6 hours. SE, short exposure. LE, long exposure. (L) Ferroptosis sensitivity of the indicated DLD1 cells, measured as percentage cell death upon mock, Erastin (5 μM) or RSL3 (0.5 μM) treatment for 24 hours. All error bars in this figure represent mean + SD, n = 3.

Fig. 3. Mitochondrial NADP(H) depletion results in proline auxotrophy. (A and B) Cell proliferation measured as cell number fold change (Day 4/Day 0) of T47D cells with sgCtrl, sgNADK2-1, or sgNADK2-2, cultured in the indicated medium and supplementation. LA, lipoic acid. Pyr, pyruvate. Cu, cupric sulfate. Zn, zinc sulfate. B12, vitamin B12. A, alanine. D, aspartate. N, asparagine. E, glutamate. P, proline. All supplements are added at the concentrations present in DMEM/F12. (C) Proline abundance measured by GC-MS in the indicated T47D cells cultured in DMEM. (D to F) (D) Western blot, (E) proline abundance measured by GC-MS, and (F) cell proliferation of DMEM-cultured T47D cells with sgCtrl or sgNADK2-2 and ectopically expressing vector or NADK2 cDNA resistant to sgNADK2-2 mediated CRISPR-Cas9 genome editing. (G to I) (G) Western blot, (H) proline abundance measured by GC-MS, and (I) cell proliferation of DMEM-cultured T47D cells with sgCtrl, sgNADK2-1, or sgNADK2-2 and ectopically expressing vector or the POS5 cDNA. All error bars in this figure represent mean + SD, n = 3. In (A), (B), (C), (H) and (I), one-way ANOVA was performed. In (E) and (F), two-sided *t*-test was performed with Welch's correction. ***P* < 0.01; ****P* < 0.001; n.s., *P* > 0.05.

The mitochondrial NADP(H) pool is required to support proline biosynthesis and collagen production

Fig. 4. The mitochondrial NADP(H) pool is required to support proline biosynthesis and collagen production. (A) Heatmap representing changes of metabolite levels measured by GC-MS in T47D cells with sgCtrl, sgNADK2-1, or sgNADK2-2 cultured in DMEM for 48 hours. The average of 3 biological replicates is shown. For each metabolite, values of sgNADK2-1 and sgNADK2-2 cells are shown as log₂ (fold change) relative to the value of sgCtrl cells. (B) Changes of metabolite levels measured by GC-MS in DMEM/F12 medium used to culture T47D cells with sgCtrl, sgNADK2-1, or sgNADK2-2 for 48 hours. (C and D) (C) proline and (D) glutamate data from (B) re-plotted as normalized values to sgCtrl cells. (E) Proline abundance measured by GC-MS in xenograft tumors formed by CS1 cells with sgCtrl or sgNADK2-2. (F) Scheme of proline biosynthesis pathway in the mitochondria. (G to J) Relative total level and isotopologue distribution of the indicated metabolites measured by LC-MS in MEFs with sgCtrl, sgNadk2-1, or sgNadk2-2, cultured in DMEM containing [U-¹³C]glutamine for 8 hours. (K) Western blot of the indicated MEFs, cultured in DMEM or DMEM supplemented with 300 μM proline. (L) Scheme of ECM extraction and collagen staining in cells and under conditions described in (M). (M) Secreted collagen levels quantified by picro sirius red staining in extracellular matrix (ECM) derived from MEFs with sgCtrl, sgNadk2-1, or sgNadk2-2, cultured for 48 hours in DMEM or DMEM supplemented with 300 μM proline, in the presence of 50 μM ascorbate. (N) Pearson correlation of NADK2 mRNA level and forced vital capacity (FVC) before bronchodilator (pre-BD) as percentage of what was predicted for each patient. Data from GSE32537. (O) Pearson correlation of NADK2 mRNA level and diffusing capacity for carbon monoxide (DLCO) as percentage of what was predicted for each patient. Data from GSE32537. Error bars in (E) represent mean ± SD, n = 10. All other error bars in this figure represent mean + SD, n = 3. In (B to D), one-way ANOVA was performed. In (E) and (M), two-sided t-test was performed with Welch's correction. *P<0.05; **P<0.01; ***P<0.001.